Immatics Receives $58 Million in Financing to Develop T-Cell Receptor Based Immunotherapies

0
381

Immatics, a leading company in the field of cancer immunotherapy, announced yesterday the completion of its Series E financing, raising $58 million.

The Series E funding was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, AT Impf GmbH and others. This latest financing was also strongly supported by new life science investors and Amgen, a world-leading biotechnology company and strategic partner of Immatics.

Immatics will use the proceeds of the Series E financing to:

  • Progress its pipeline of adoptive cell therapies in a series of clinical trials. This will include the candidates IMA101, an ACTolog® endogenous T-cell therapy, and IMA201, an ACTengine® approach, based on transducing a patient’s own T-cells to express a tumor-specific exogenous T-cell receptor (TCR) and redirecting activated T-cells to the tumor sites.
  • Continue to develop its pipeline of bispecific TCR candidates, with the aim to redirect and activate the T-cell response towards cancer cells expressing specific tumor targets.
  • Continue the discovery and validation of novel tumor targets for cancer immunotherapy, using its world-leading XPRESIDENT® technology.

Peter Chambré, Chairman of Immatics, said: “We are very pleased to have been supported in this financing by our existing shareholders and a number of major new shareholders, including Amgen, with whom the Company signed a strategic collaboration earlier this year. During the period covered by this financing, we expect to receive initial patient data from the current Immatics’ IMA101 and IMA201 adoptive cell therapy clinical trials, as well as commencing trials of further ACTengine® candidates.

We also expect to demonstrate proof of principle for our novel bispecific TCR candidates that, we believe, have significant potential in this emerging field. Immatics’ adoptive cell therapies and bispecific TCR candidates are tailored to address cancer targets identified and validated using XPRESIDENT®.”